Grifols is a global plasma-derived medicines company that collects human plasma and manufactures therapies for immunology, hematology, critical care, and related specialties. It also supplies diagnostic and hospital pharmacy solutions linked to the blood and plasma value chain. Scale in collection centers and fractionation capacity is a core feature of its position among large biopharma plasma specialists.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 1,786 | — | 60 | — |
| Q2 2025 | 1,891 | — | 117 | — |
| Q4 2025 | 1,981.7 | — | 98.3 | — |
| Q1 2026 | 1,700 | -4.8% | 73 | 21.7% |
| Q2 2026 | 1,874 | -0.9% | 155 | 32.5% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Mercury Systems, Inc. (MRCY), PriceSmart, Inc. (PSMT), Core Scientific, Inc. (CORZ), Rigetti Computing, Inc. (RGTI), Avis Budget Group, Inc. (CAR), Sabra Health Care REIT, Inc. (SBRA)